Stelara secondary patents biosimilar entry?

It sounds like you’re asking about secondary (follow‑on) patent coverage and/or when a biosimilar can enter for Stelara (ustekinumab). I can help, but I need one key detail:

Which country/market are you asking about (US, EU, UK, etc.)?
Patent status and biosimilar “entry” timing differ a lot by jurisdiction.

In the meantime, here’s the general way “secondary patents” affect biosimilar entry for biologics like Stelara:

What “secondary patents” usually mean

After the original (“primary”) patents on a drug expire, companies may still have additional patents covering things like:

• new formulations (e.g., prefilled syringe vs vial)
• new dosage regimens or maintenance dosing schedules
• combination therapy uses
• new indications (e.g., additional approved diseases)
• manufacturing/process improvements (CMC-related patents)

These can delay biosimilar launch if a biosimilar would infringe them (or if courts/agreements delay entry).

How biosimilar entry timing is typically determined (high level)

• In the US, biosimilar products are evaluated under the BPCIA framework, where patent listings and “notice of commercial marketing” interact with court/settlement outcomes.
• In other regions, national rules on exclusivity and patent linkage may differ.

What I can do for you

If you tell me the country (and ideally whether you mean US FDA biosimilar entry or EU market authorization), I can:

• identify the biosimilar candidates for Stelara in that market,
• summarize what “secondary patents” are commonly relevant,
• explain how those patents could affect launch date (or whether they’re likely to have done so via settlement/court outcomes),
• point you to the right resources (e.g., patent registers / Orange Book-type equivalents / relevant litigation).

Reply with:

1. US, EU, UK, or another country?
2. Are you asking about current/actual entry dates or about potential barriers (secondary patents) preventing entry?